Compounds > mazapertine succinate
Page last updated: 2024-11-06

mazapertine succinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mazapertine succinate is a potent and selective antagonist of the 5-HT2C receptor. It has shown promising preclinical results in animal models of anxiety and depression. Its synthesis involves a complex multi-step process starting with a chiral building block. Mazapertine succinate is being studied for its potential therapeutic benefits in treating anxiety disorders and major depressive disorder. Its ability to block 5-HT2C receptors is believed to contribute to its antidepressant and anxiolytic effects. The compound is also being investigated for its potential to improve cognitive function and social behavior in patients with autism spectrum disorder.'

mazapertine succinate: an arylpiperazine derivative; a dopamine D2 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60819
CHEMBL ID2106947
SCHEMBL ID120658
MeSH IDM0230269

Synonyms (18)

Synonym
134208-18-7
D02670
mazapertine succinate (usan)
mazapertine succinate
1-(alpha-(4-(o-isopropoxyphenyl)-1-piperazinyl)-m-toluoyl)piperidine succinate (1:1)
piperidine, 1-(3-((4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)methyl)benzoyl)-, butanedioate (1:1)
unii-naa0o2xc28
rwj 37796
mazapertine succinate [usan]
naa0o2xc28 ,
CHEMBL2106947
rwj-37796
1-(.alpha.-(4-(o-isopropoxyphenyl)-1-piperazinyl)-m-toluoyl)piperidine succinate (1:1)
SCHEMBL120658
DTXSID00158595
(3-((4-(2-isopropoxyphenyl)piperazin-1-yl)methyl)phenyl)(piperidin-1-yl)methanone succinate
butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
Q27284763

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5h after dosing and plasma concentrations were consistently higher in female rats."( Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats.
Caldwell, GW; Diane Gauthier, A; Jones, WJ; Leo, GC; Masucci, JA; McKown, LA; Reitz, AB; Wu, WN, 2006)		0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (87.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
7-hydroxy-2-n,n-dipropylaminotetralin
7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation		1.9810tetralins
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		1.9810aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide: a dopamine receptor imaging agent; RN refers to (S)-isomer; RN & structure given in first source		3.7820
raclopride
Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.		1.9810salicylamides
piperidines
Piperidines: A family of hexahydropyridines.		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Hypotension, Postural
[description not available]		03.3711
Hypotension, Orthostatic
A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE.		03.3711
Dementia Praecox
[description not available]		01.9910
Hyponatremia
Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)		01.9910
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		01.9910
Anochlesia
[description not available]		01.9910